Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 56

Sort by

Sort Order Select

Journal Articles

Early Initiation of Treatment with Rivipansel for Acute Vaso-Occlusive Crisis in Sickle Cell Disease (SCD) Achieves Earlier Discontinuation of IV Opioids and Shorter Hospital Stay: Reset Clinical Trial Analysis

Carlton D. Dampier, MD, Marilyn J. Telen, MD, Ted Wun, MD, Wally R Smith, MD, R. Clark Brown, MD PhD, Payal Desai, MD, Fuad A El Rassi, MD, Julie Kanter, MD, Beng R. Fuh, MD, Yves D. Pastore, MD, Jennifer A. Rothman, MD, James G. Taylor, MD, David Readett, BM, BS, MRCP, Jay N Lozier, MDPhD, John L. Magnani, PhD, Helen M Thackray, MD, Kathryn L. Hassell, MD

Blood (2020) 136 (Supplement 1): 18–19.

https://doi.org/10.1182/blood-2020-134803

Published: 2020

Journal Articles

Resolution of Serious Vaso-Occlusive Pain Crises and Reduction in Patient-Reported Pain Intensity: Results from the Ongoing Phase 1/2 HGB-206 Group C Study of LentiGlobin for Sickle Cell Disease (bb1111) Gene Therapy

Alexis A. Thompson, MD, Mark C. Walters, MD, Markus Y Mapara, MD PhD, Janet L. Kwiatkowski, MD MSCE, Lakshmanan Krishnamurti, MD, Banu Aygun, MD, Kimberly A. Kasow, DO, Stacey Rifkin-Zenenberg, DO, Manfred Schmidt, PhD, Jay DelCarpini, Francis J. Pierciey, Jr., Alexandra L. Miller, Meghan E. Gallagher, MSc, Ren Chen, Sunita Goyal, MD, Julie Kanter, MD, John F. Tisdale, MD

Blood (2020) 136 (Supplement 1): 16–17.

https://doi.org/10.1182/blood-2020-134940

Published: 2020

Journal Articles

Predictors of Maternal Morbidity Among Participants Enrolled in the Sickle Cell Disease Implementation Consortium Registry

Rita V Masese, MSc,MD, Dominique Bulgin, BSN, RN, Liliana Preiss, Mitchell Knisely, PhD RN, Eleanor Stevenson, PhD RN, Jane S. Hankins, MD MS, Marsha Treadwell, PhD, Allison A. King, MDMPH,PhD, Victor R. Gordeuk, MD, Julie Kanter, MD, Robert Gibson, MD, Jeffrey A. Glassberg, MD, Paula Tanabe, PhDRN, Nirmish Shah, MD

Blood (2020) 136 (Supplement 1): 3.

https://doi.org/10.1182/blood-2020-140743

Published: 2020

Journal Articles

Improvements in Health-Related Quality of Life for Patients Treated with LentiGlobin for Sickle Cell Disease (bb1111) Gene Therapy

Julie Kanter, MD, John F. Tisdale, MD, Markus Y Mapara, MD PhD, Janet L. Kwiatkowski, MD MSCE, Lakshmanan Krishnamurti, MD, Ren Chen, Meghan E. Gallagher, MSc, Yuchen Ding, PhD, Sunita Goyal, MD, Clark Paramore, MPH, Alexis A. Thompson, MD, Mark C. Walters, MD

Blood (2020) 136 (Supplement 1): 10.

https://doi.org/10.1182/blood-2020-136193

Published: 2020

Journal Articles

Assessment of Impact of a mHealth Self-Management Intervention for Children with Sickle Cell Disease

Shannon Phillips, PhDRN, Julie Kanter, MD, Martina Mueller, PhD, Kenneth Ruggiero, PhD, Teresa Kelechi, PhD RN, FAAN

Blood (2020) 136 (Supplement 1): 11–12.

https://doi.org/10.1182/blood-2020-141945

Published: 2020

Journal Articles

Effect of Sickle Cell Related Therapies on Growth in Children with Sickle Cell Disease: Evidence from the Displace Study

Najibah Aliyu Galadanci, MBBS,MPH, Maira Sohail, MPH, Oluwasegun Philip Akinyelure, MBBS, MPH, Akinyemi I. Ojesina, MBBS,PhD, Julie Kanter, MD

Blood (2020) 136 (Supplement 1): 21.

https://doi.org/10.1182/blood-2020-140582

Published: 2020

Journal Articles

Study Design and Initial Baseline Characteristics in Solace-Kids: Crizanlizumab in Pediatric Patients with Sickle Cell Disease

Matthew M. Heeney, MD, David C. Rees, MD, Mariane de Montalembert, MD PhD, Isaac Odame, MD, R. Clark Brown, MD PhD, Yasser Wali, MD, Thu Thuy Nguyen, Du Lam, MD, Raquel Merino Herranz, Julie Kanter, MD

Blood (2020) 136 (Supplement 1): 22–24.

https://doi.org/10.1182/blood-2020-137081

Published: 2020

Journal Articles

Evaluation of STOP Protocol Implementation for Abnormal TCD in Children with Sickle Cell Anemia at Risk for Stroke: Displace Consortium

Shannon Phillips, PhDRN, Alyssa M Schlenz, PhD, Mary Dooley, MS, Martina Mueller, PhD, Logan P Sirline, MPH, Cathy L Melvin, PhD MPH, Robert J Adams, MD MS, Julie Kanter, MD

Blood (2020) 136 (Supplement 1): 22–23.

https://doi.org/10.1182/blood-2020-141970

Published: 2020

Journal Articles

Hydroxyurea Use and Outcomes of Pregnancy in Sickle Cell Disease

Victor R. Gordeuk, MD, Barbara Kroner, PhD, Norma Pugh, PhD, Jane S. Hankins, MD MS, Abdullah Kutlar, MD, Allison A. King, MDMPH,PhD, Nirmish Shah, MD, Julie Kanter, MD, Jeffrey Glassberg, MD, Marsha Treadwell, PhD

Blood (2020) 136 (Supplement 1): 33.

https://doi.org/10.1182/blood-2020-143315

Published: 2020

Journal Articles

Sickle Stroke Screen: A Patient-Centered Educational Initiative for Children with Sickle Cell Anemia in the Displace Consortium

Alyssa M Schlenz, PhD, Shannon Phillips, PhDRN, Martina Mueller, PhD, Cathy L Melvin, PhD MPH, Robert J Adams, MD MS, Julie Kanter, MD

Blood (2020) 136 (Supplement 1): 43–44.

https://doi.org/10.1182/blood-2020-141963

Published: 2020

Journal Articles

Pharmacokinetics/Pharmacodynamics, Safety and Efficacy of Crizanlizumab in Patients with Sickle Cell Disease and a History of Vaso-Occlusive Crises: Results from the Phase II, Multicenter, Open-Label Solace-Adults Study

Darla Liles, MD, Kim Smith-Whitley, MD, R Clark Brown, MD PhD, Nirmish Shah, MD, Santosh M Nair, MD, Chiaki Tanaka, PhD, Shankaranand Bodla, Gessami Sanchez-Olle, PhD, Urs Albers, PhD, Julie Kanter, MD

Blood (2020) 136 (Supplement 1): 17–19.

https://doi.org/10.1182/blood-2020-137434

Published: 2020

Journal Articles

Sex Based Differences in Sickle Cell Disease

Rita V Masese, MSc,MD, Dominique Bulgin, BSN, RN, Mitchell Knisely, PhD RN, Liliana Preiss, Eleanor Stevenson, PhD RN, Jane S. Hankins, MD MS, Marsha Treadwell, PhD, Allison A. King, MDMPH,PhD, Victor R. Gordeuk, MD, Julie Kanter, MD, Robert Gibson, MD, Jeffrey A. Glassberg, MD, Paula Tanabe, PhDRN, Nirmish Shah, MD

Blood (2020) 136 (Supplement 1): 37.

https://doi.org/10.1182/blood-2020-140896

Published: 2020

Journal Articles

Severity Classification for Sickle Cell Disease: A RAND/UCLA Modified Delphi Panel

Nirmish Shah, David Beenhouwer, Michael S Broder, MD MSHS, Lanetta Bronte-Hall, Laura De Castro, MD MHSc, Sarah N Gibbs, Victor R Gordeuk, MD, Julie Kanter, MD, Elizabeth S Klings, MD, Thokozeni Lipato, MD, Deepa Manwani, MD, Brigid Scullin, Irina Yermilov, Wally R Smith, MD

Blood (2019) 134 (Supplement_1): 415.

https://doi.org/10.1182/blood-2019-121556

Published: 2019

Journal Articles

Randomized Controlled Trial of the Efficacy and Safety of Deferiprone in Iron-Overloaded Patients with Sickle Cell Disease or Other Anemias

Blood (2019) 134 (Supplement_1): 618.

https://doi.org/10.1182/blood-2019-122062

Published: 2019

Journal Articles

Exploring the Drivers of Potential Clinical Benefit in Initial Patients Treated in the Hgb-206 Study of Lentiglobin for Sickle Cell Disease (SCD) Gene Therapy

Mark C. Walters, MD, John F. Tisdale, MD, Janet L. Kwiatkowski, MD MSCE, Lakshmanan Krishnamurti, MD, Markus Y. Mapara, MD PhD, Manfred Schmidt, PhD, Alexandra L. Miller, Francis J. Pierciey, Jr., Wenmei Huang, PhD MS, Jean-Antoine Ribeil, MD PhD, Julie Kanter, MD, Alexis A. Thompson, MD MPH

Blood (2019) 134 (Supplement_1): 2061.

https://doi.org/10.1182/blood-2019-128814

Published: 2019

Journal Articles

Crizanlizumab Treatment Is Associated with Clinically Significant Reductions in Hospitalization in Patients with Sickle Cell Disease: Results from the Sustain Study

Kenneth I. Ataga, MD, Abdullah Kutlar, MD, Laurie DeBonnett, MD, Jeremie Lincy, Julie Kanter, MD

Blood (2019) 134 (Supplement_1): 2289.

https://doi.org/10.1182/blood-2019-125868

Published: 2019

Journal Articles

Characteristics of Children with Abnormal TCD in the Modern Era: Results from the Displace Consortium

Julie Kanter, MD, Mary Dooley, MS, Logan P Sirline, MPH, Martina Mueller, PhD, Shannon Phillips, PhD RN, Alyssa M Schlenz, PhD, Cathy Melvin, PhD MPH, Robert J. Adams, MD MS

Blood (2019) 134 (Supplement_1): 2270.

https://doi.org/10.1182/blood-2019-129951

Published: 2019

Journal Articles

Crizanlizumab 5.0 Mg/Kg Exhibits a Favorable Safety Profile in Patients with Sickle Cell Disease: Pooled Data from Two Phase II Studies

Julie Kanter, MD, Darla K Liles, MD, Kim Smith-Whitley, MD, Clark Brown, MD PhD, Abdullah Kutlar, MD, Brian Elliott, Amit Shah, Jeremie Lincy, Susan Poggio, Kenneth I. Ataga, MBBS

Blood (2019) 134 (Supplement_1): 991.

https://doi.org/10.1182/blood-2019-123965

Published: 2019

Journal Articles

Resolution of Sickle Cell Disease Manifestations in Patients Treated with Lentiglobin Gene Therapy: Updated Results from the Phase 1/2 Hgb-206 Group C Study

Julie Kanter, MD, John F. Tisdale, MD, Markus Y. Mapara, MD PhD, Janet L. Kwiatkowski, MD MSCE, Lakshmanan Krishnamurti, MD, Manfred Schmidt, PhD, Alexandra L. Miller, Francis J. Pierciey, Jr., Wenmei Huang, PhD MS, Jean-Antoine Ribeil, MD PhD, Alexis A. Thompson, MD MPH, Mark C. Walters, MD

Blood (2019) 134 (Supplement_1): 990.

https://doi.org/10.1182/blood-2019-128894

Published: 2019

Journal Articles

The Relationships between Target Gene Transduction, Engraftment of HSCs and RBC Physiology in Sickle Cell Disease Gene Therapy

Melissa Bonner, PhD, Julie Kanter, MD, Elizabeth Macari, PhD, Ricky Lane, Gretchen Lewis, BMBS, Paige Coles, Sarah Kassenaar, Sai Mynampati, MS, Robert Schulze, Madison Hebert, Mark C. Walters, MD, Alexis A. Thompson, MD MPH, Mohammed Asmal, MD PhD, John F. Tisdale, MD, Francis J. Pierciey, Jr.

Blood (2019) 134 (Supplement_1): 206.

https://doi.org/10.1182/blood-2019-129124

Published: 2019

NARROW

Early Initiation of Treatment with Rivipansel for Acute Vaso-Occlusive Crisis in Sickle Cell Disease (SCD) Achieves Earlier Discontinuation of IV Opioids and Shorter Hospital Stay: Reset Clinical Trial Analysis

Resolution of Serious Vaso-Occlusive Pain Crises and Reduction in Patient-Reported Pain Intensity: Results from the Ongoing Phase 1/2 HGB-206 Group C Study of LentiGlobin for Sickle Cell Disease (bb1111) Gene Therapy

Predictors of Maternal Morbidity Among Participants Enrolled in the Sickle Cell Disease Implementation Consortium Registry

Improvements in Health-Related Quality of Life for Patients Treated with LentiGlobin for Sickle Cell Disease (bb1111) Gene Therapy

Assessment of Impact of a mHealth Self-Management Intervention for Children with Sickle Cell Disease

Effect of Sickle Cell Related Therapies on Growth in Children with Sickle Cell Disease: Evidence from the Displace Study

Study Design and Initial Baseline Characteristics in Solace-Kids: Crizanlizumab in Pediatric Patients with Sickle Cell Disease

Evaluation of STOP Protocol Implementation for Abnormal TCD in Children with Sickle Cell Anemia at Risk for Stroke: Displace Consortium

Hydroxyurea Use and Outcomes of Pregnancy in Sickle Cell Disease

Sickle Stroke Screen: A Patient-Centered Educational Initiative for Children with Sickle Cell Anemia in the Displace Consortium

Pharmacokinetics/Pharmacodynamics, Safety and Efficacy of Crizanlizumab in Patients with Sickle Cell Disease and a History of Vaso-Occlusive Crises: Results from the Phase II, Multicenter, Open-Label Solace-Adults Study

Sex Based Differences in Sickle Cell Disease

Severity Classification for Sickle Cell Disease: A RAND/UCLA Modified Delphi Panel

Randomized Controlled Trial of the Efficacy and Safety of Deferiprone in Iron-Overloaded Patients with Sickle Cell Disease or Other Anemias

Exploring the Drivers of Potential Clinical Benefit in Initial Patients Treated in the Hgb-206 Study of Lentiglobin for Sickle Cell Disease (SCD) Gene Therapy

Crizanlizumab Treatment Is Associated with Clinically Significant Reductions in Hospitalization in Patients with Sickle Cell Disease: Results from the Sustain Study

Characteristics of Children with Abnormal TCD in the Modern Era: Results from the Displace Consortium

Crizanlizumab 5.0 Mg/Kg Exhibits a Favorable Safety Profile in Patients with Sickle Cell Disease: Pooled Data from Two Phase II Studies

Resolution of Sickle Cell Disease Manifestations in Patients Treated with Lentiglobin Gene Therapy: Updated Results from the Phase 1/2 Hgb-206 Group C Study

The Relationships between Target Gene Transduction, Engraftment of HSCs and RBC Physiology in Sickle Cell Disease Gene Therapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only